Colin H Quinn

11PUBLICATIONS
26CO-AUTHORS
Haematological tumoursMolecular targetsWork integrated learning (incl. internships)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 14, 2025
A Novel Rexinoid Agonist, UAB116, Decreases Metastatic Phenotype in Hepatoblastoma by Inhibiting the Wnt/β-Catenin Pathway via Upregulation of TRIM29.

Swatika Butey, Morgan L Brown, Janet R Julson

|Nov 27, 2024
Novel PP2A-Activating Compounds in Neuroblastoma.

Nazia Nazam, Laura V Bownes, Janet R Julson

|Oct 25, 2024
The Impact of Peer-Led Learning Groups on First-Year Medical Students.

Sam E Gary, Samuel F Chang, Colin H Quinn

|Aug 29, 2024
Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma.

Amber B Jones, Kaysaw Tuy, Cyntanna C Hawkins

|Jan 11, 2024
PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.

Janet R Julson, Colin H Quinn, Swatika Butey

|Apr 23, 2022
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma.

Laura V Bownes, Raoud Marayati, Colin H Quinn

Pageof 2

Frequent Collaborators

10 joint publications

Elizabeth A Beierle

7 joint publications

Raoud Marayati

4 joint publications

Laura V Bownes

3 joint publications

Hooper R Markert